Experimental Genetic

5 trials

Sponsors

Thailand Science Research and Innovation, Inter Pharma Plc., Program Management Unit Competitiveness, Investigator Initiated Trial

Conditions

240 patients whose blood pressure levels were monitored and were placed them into three groups: normal (74 samples), pre-DM (93 samples) and type 2 DM (73 samples). Type 2 DMPatients with advanced Parkinson&#039The newly diagnose with MM The newly diagnose with plasma cell disorder Relapse MM patient Thai population Multiple Myeloma Next Generation Sequencing Somatic mutationTransfusion-Dependent beta-Thalassemia Thalassemiaheterozygous beta 0-thalassemia and hemoglobin E transfusion-dependent beta-thalassemia (TDT) TDT, Beta 0/Beta E TDT

Early Phase 1

Utilizing Next Generation Sequencing to Evaluate Genomic Complexity in Thai Patients with Multiple Myeloma

Active, not recruitingTCTR20211020003

The newly diagnose with MM The newly diagnose with plasma cell disorder Relapse MM patient Thai population Multiple Myeloma Next Generation Sequencing Somatic mutation

Start: 2020-01-01Target: 20Updated: 2026-08-03

Alu methylation levels in case follow-up of type 2 Diabetes Mellitus

Active, not recruitingTCTR20220324001

Thailand Science Research and Innovation240 patients whose blood pressure levels were monitored and were placed them into three groups: normal (74 samples), pre-DM (93 samples) and type 2 DM (73 samples). Type 2 DM

Start: 2015-12-01Target: 240Updated: 2026-08-03

Phase 1

A Phase I/II Prospective, Single Arm, Multi Center, Open-Label Clinical Trial Evaluating the Safety and Efficacy of GT0003X in Patients with Parkinson's Disease

RecruitingTCTR20250401007

Inter Pharma Plc.Patients with advanced Parkinson&#039

Start: 2026-01-15Target: 6Updated: 2026-08-03

Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of a Transplantation of Autologous CD34+ Human Hematopoietic Stem Cells Transduced Ex Vivo with a beta A-T87Q-Globin Lentiviral Vector (BG1 Gene Therapy Product) in Patients with beta0/betaE Transfusion-Dependent beta-Thalassemia

Active, not recruitingTCTR20250709014

Program Management Unit Competitivenessheterozygous beta 0-thalassemia and hemoglobin E transfusion-dependent beta-thalassemia (TDT) TDT, Beta 0/Beta E TDT

Start: 2025-05-19Target: 6Updated: 2026-08-03

A Phase I Clinical Trial to Evaluate Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (RM-001) in Transfusion-Dependent beta Thalassemia Patients

Active, not recruitingTCTR20250828001

Investigator Initiated TrialTransfusion-Dependent beta-Thalassemia Thalassemia

Start: 2026-01-01Target: 5Updated: 2026-08-03